Infectious Opportunity? Nabi Biopharma Sells Staph A Vaccine To Glaxo For $46M
This article was originally published in The Pink Sheet Daily
Executive Summary
The sale will enable the little company to focus solely on its nicotine-addiction vaccine candidate, NicVAX.